The global chronic wound care market size is expected to rise at a CAGR of 3.8% during the projected period 2023 to 2033. The market value is projected to increase from US$ 17,272.4 million in 2023 to US$ 25,042.5 million by 2033. The chronic wound care market was valued at US$ 16,689.3 million in 2022 and is anticipated to exhibit a y-o-y growth of 3.5% in 2023.
| Attributes | Key Insights |
|---|---|
| Chronic Wound Care Market Size (2022A) | US$ 16,689.3 million |
| Estimated Chronic Wound Care Market Value (2023E) | US$ 17,272.4 million |
| Projected Chronic Wound Care Market Value (2033F) | US$ 25,042.5 million |
| Value-based CAGR (2023 to 2033) | 3.8% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Pharmaceutical goods and therapies, specially created for the management and treatment of chronic wounds, are set to be included in the chronic wound care pharmaceutical market. Growing cases of sports injuries, rising diabetes prevalence, and shifting lifestyles are expected to propel market expansion.
The incidence rate of chronic wounds is predicted to rise globally due to the rising rates of chronic diseases such as cancer, diabetes, and several autoimmune disorders. The surging incidence of non-communicable diseases is attributed to factors such as antimicrobial resistance, unhealthy and sedentary lifestyles, and alcohol and tobacco use.
The COVID-19 pandemic has raised the demand for protective clothing, hand sanitizers, respiratory supplies, diagnostic and laboratory disposables, and medicine delivery products. In the forecast period, it is projected that growing consumer awareness of the advantages of hygiene and cleanliness will propel the market for hand sanitizers, clothing, and sterilization supplies.
Another important aspect that is expected to propel market expansion is the increasing prevalence of obesity, which is linked to lower extremity amputations and chronic wounds. Due to decreased vascular activity in adipose tissue, obese individuals are more likely to develop pressure ulcers. The inability of these individuals to adjust their position in bed serves as a prelude to injuries caused by pressure.
The creases in their skin can create the perfect environment for microbes to proliferate. These microbes break down the skin, which results in ulcers, which can increase the demand for these solutions, which will push the market.
The chronic wound care sector is expanding as a result of technological developments in treatment choices. The potential for patient outcomes, healing time, and effectiveness of wound care to be dramatically improved by technological advancements is great.
For instance, TRUSHIELD NXT, a surgical wound dressing with a 3D hydrocellular substrate and distinct infection prevention technology, was introduced by Healthium Medtech Limited in October 2021.
Consumers are anticipated to be encouraged to use cutting-edge wound care solutions for the urgent treatment of diabetic foot ulcers and other ailments. This is attributed to key players' investments in research and development and the introduction of a range of novel wound-healing products, including foam dressings and others.
In developed nations, a sizable amount of healthcare spending is allocated to treating wounds. According to studies conducted by Health Science Reports 2022, 50% of hospitalized patients have wounds, compared to 1% to 2% of the general population worldwide who live in affluent nations.
Chronic wounds take longer than the anticipated 30 days to heal. Technologies have been created to solve difficulties in wound care to reduce discomfort, accelerate healing, or reduce wound infections.
It is clear from these trends and advancements in wound care that the global healthcare sector is aggressively addressing the difficulties in treating wounds. It aims to improve patient outcomes and raise the standard of care for those with chronic wounds.
Principal Consultant
The global chronic wound care market recorded a CAGR of 2.2% in the historical period from 2018 to 2022. The chronic wound care market value was around 63.8% of the global advance wound dressing market.
The global wound dressing market was worth US$ 26,165.24 million in the same period. The increasing incidence of diabetic foot ulcers in the elderly in developing countries is leading to a growing demand for antimicrobial wound dressing products.
| Attributes | Details |
|---|---|
| Historical CAGR (2018 to 2022) | 2.2% |
| Forecast CAGR (2023 to 2033) | 3.8% |
For instance, research published by the National Center for Biotechnology Information in August 2021 states that 1.0% of diabetics in the United States suffer an amputation, and 5.0% of diabetics in the country have foot ulcers. Diabetic foot ulcers can also lead to lower limb amputations and gangrene. These are the most common conditions in hospital wards in less developed countries, which can spur the demand for antimicrobial wound dressing products.
The market for chronic wound care medications is propelled by continued efforts to discover novel and efficient treatment alternatives. It is also projected to be supported by the rising expenditure in healthcare facilities and the expanding use of cutting-edge wound care technologies.
Such advancements are intended to improve patient outcomes and reduce healthcare expenses related to managing chronic wounds. These are further expected to raise the general standard of living for those who have chronic wounds.
| Attributes | Key Factors |
|---|---|
| Chronic Wound Care Market Trends |
|
| Growth Hindrances |
|
| Upcoming Opportunities |
|
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
In the table below, the CAGRs of the top six countries are given for the review period 2023 to 2033. China and India are expected to remain dominant by exhibiting CAGRs of 8.9% and 9.1%, respectively. The United States and Japan are anticipated to follow with CAGRs of 1.2% and 4.8%, respectively.
| Country | Value-based CAGR |
|---|---|
| United States | 1.2% |
| Germany | 1.1% |
| United Kingdom | 0.9% |
| Japan | 4.8% |
| China | 8.9% |
| India | 9.1% |
The United States dominated the global chronic wound care market with a 34.9% share in 2022. It is projected to continue experiencing high growth throughout the forecast period. The North America market is expected to surge with a CAGR of 1.2% over the forecast period due to the rising prevalence of chronic wounds.
The rising incidence of chronic diseases such as diabetes, obesity, and vascular diseases has contributed to an increasing number of patients with chronic wounds. This has created a substantial demand for effective wound care drugs in the market.
The growing awareness among healthcare professionals and patients about the importance of early and effective wound management has led to an increased demand for advanced wound care products and drugs. These would help promote faster healing and reduce the risk of complications.
China dominates the global chronic wound care market and held a 4.2% market share in 2022. It is projected to continue experiencing high growth throughout the forecast period.
The government of China has been focusing on healthcare reforms to improve the accessibility and quality of healthcare services across the country. These initiatives are set to create a conducive environment for manufacturers to introduce and promote chronic wound care in the market.
China's pharmaceutical market has been rapidly expanding, driven by a combination of factors, including increased healthcare expenditure, a growing middle class, and a greater focus on healthcare research and development. This presents an opportunity for manufacturers to tap into the market potential and cater to the growing demand for chronic wound care.
India held about 4.1% share of the global market in 2022 and is projected to showcase robust growth during the forecast period. The prevalence of chronic conditions such as diabetes, obesity, and cardiovascular diseases is rising in India. These conditions often lead to chronic wounds, creating a significant demand for effective wound care drugs and treatments.
There has been a significant increase in awareness among healthcare professionals and patients regarding the importance of early intervention and effective wound management in India. This heightened awareness has led to a greater demand for advanced wound care products and drugs that facilitate faster healing and reduce the risk of complications.
In 2022, Germany held a dominant revenue in the chronic wound care market and is expected to surge at a CAGR of 1.1% through 2033. There are now more specialized wound treatment clinics and facilities available in Germany. These clinics would provide cutting-edge care and knowledge about handling long-term wounds.
Advanced wound dressings with antibacterial qualities are in demand as infection control is crucial to wound care. International enterprises, research centers, and healthcare organizations often collaborate with each other in Germany. These collaborations seek to improve wound care treatments by utilizing knowledge and technology.
In Germany, education and awareness campaigns about the care and prevention of wounds are essential. Patients and medical personnel can both gain from continuing education regarding optimal techniques for managing wounds.
In Germany, telemedicine and remote monitoring technologies are becoming increasingly popular. The use of these technologies eliminates the necessity for in-person visits for consultations and wound evaluations.
Regenerative medicine and tissue engineering, which can find use in the treatment of chronic wounds, have attracted considerable interest in Germany. Healthcare professionals are becoming more conscious of environmental sustainability. Eco-friendly manufacturing methods can provide them with a competitive advantage.
Japan’s chronic wound care market is poised to exhibit a CAGR of 4.8% during the assessment period. Due to its high elderly population, Japan has a substantial market for services and goods related to chronic wound care. The need for enhanced wound care treatments is set to be fueled by the rise of chronic disorders such as diabetes and vascular diseases.
Japan regulates healthcare items under strict guidelines. In order for manufacturers to promote and distribute wound care products in the nation, they must abide by the Pharmaceutical Affairs Law and other pertinent rules.
The country’s market is distinguished by a significant focus on innovation in technology. There is a market for advanced wound care goods, such as wound healing devices and bioengineered dressings.
Buyers in Japan are renowned for having a taste for premium goods. For manufacturers to be successful in this industry, strict standards of quality and safety must be upheld.
In Japan, home healthcare is becoming more popular due to the country's increasing aging population. This involves the requirement for at-home, efficacious treatments for chronic wound care.
The table below signifies the leading sub-categories under product, wound type, and distribution channel categories in the chronic wound care market. Advanced wound dressing is expected to dominate the market for chronic wound care by exhibiting a 3.0% CAGR in the evaluation period. Under the wound type category, the other ulcers segment is projected to lead the global market at a 1.8% CAGR.
| Segment | Value CAGR |
|---|---|
| Advanced Wound Dressings (Product) | 3.0% |
| Other Ulcers (Wound Type) | 1.8% |
| Hospitals (Distribution Channel) | 1.2% |
Advanced wound dressings in terms of the product segment held a share of 40.9% in 2022, and the same trend is set to be followed over the forecast period. The increasing incidence of diabetic foot ulcers in the elderly in developing countries is leading to a steady demand for advanced wound dressing products.
According to estimates by the International Diabetes Federation, the prevalence of diabetic foot ulcers in developed countries was around 2% in 2017, while it was over 20% in resource-poor countries in the Caribbean. This is driving the demand for low-cost antimicrobial wound dressing products in inpatient care and private homes.
The other ulcers segment dominates the wound type segment and held around 49.6% market share in 2022. Increasing research and development investments in wound care are projected to boost the market for chronic wound care.
The goal of research and development is to create novel dressing materials, incorporate cutting-edge technology, and improve the antibacterial qualities of dressings. Through these expenditures, businesses want to stay competitive and meet the changing demands of both patients and healthcare professionals.
The development of antimicrobial wound dressings with improved qualities and functions is the focus of research and development spending. This includes the development of dressings with higher biocompatibility, longer wear times, improved moisture management, and simplicity of use. Also, the aim of research and development is to develop novel solutions that specifically address the needs of patients and healthcare professionals.
The hospital segment dominates in terms of end-users. The segment held about 31.4% market share in 2022. Hospitals frequently have specialized wound care units with cutting-edge technology and qualified medical staff who are committed to efficiently managing chronic wounds.
Patients with severe or complex chronic wounds frequently need inpatient care for proper monitoring and treatment, which is effectively given in hospital settings. To ensure thorough and integrated treatment regimens for patients with chronic wounds, hospitals frequently facilitate multidisciplinary collaboration among several healthcare professionals. It includes wound care specialists, nurses, and chemists; this improves patient outcomes and boosts the effectiveness of healthcare as a whole.
Collaboration among healthcare professionals from other disciplines, such as surgeons, nurses, microbiologists, and researchers, can improve patient outcomes and promote the use of novel wound care solutions, such as antimicrobial dressings.
Market participants are adopting several strategies, such as collaborations, mergers and acquisitions, and product launches, to strengthen their presence in the market. Furthermore, leading companies are capitalizing heavily on research and development to bring innovative products and advanced technology to market.
For instance,
| Attribute | Details |
|---|---|
| Chronic Wound Care Market Size (2023) | US$ 17,272.4 million |
| Chronic Wound Care Market Forecast Value (2033) | US$ 25,042.5 million |
| Value-based CAGR (2023 to 2033) | 3.8% |
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2018 to 2022 |
| Market Analysis | Value (US$ million) |
| Key Regions Covered | North America; Latin America; East Asia; South Asia Pacific; Western Europe; Eastern Europe; Central Asia; Russia and Belarus; Balkan and Baltic Countries; Middle East and Africa |
| Key Countries Covered | United States, Canada, Brazil, Mexico, Argentina, China, Japan, South Korea, India, Indonesia, Thailand, Philippines, Malaysia, Vietnam, Australia and New Zealand, Western Europe, Eastern Europe, Germany, GCC Countries, Türkiye, Northern Africa, South Africa, Israel. |
| Key Market Segments Covered | Product, Wound Type, Distribution Channel, Region |
|
Key Companies Profiled |
Teva Pharmaceuticals; Lupin Ltd; Cipla Ltd; MTF Biologics; MIMEDX Group, Inc.; Integra Lifesciences; Smith and Nephew plc; Cardinal Health Inc.; 3M; Mölnlycke Health Care; Medline Industries, Inc.; ConvaTec Group plc.; Coloplast Corp.; B. Braun Holding GmbH & Co. KG; Johnson & Johnson Innovation, LLC; Stryker Corporation; Anika Therapeutics, Inc.; Becton, Dickinson and Company; Novartis AG; Perrigo Company plc; AstraZeneca; Essity AB (BSN Medical); Boen Healthcare Co., Ltd; Hakuzo Medical Asia Co., Ltd; Organogenesis Holdings Inc.; PAUL HARTMANN AG; Alleva Medical Ltd. (Devon Medical Products); Olle Larsson Holding AG (Medela AG); Avery Dennison Corporation; Oneness Biotech; Vericel Corporation; Marine Polymer Technologies Inc.; SIGVARIS GROUP; Taro Pharmaceuticals; Prasco Laboratories. |
| Report Coverage | Market Forecast, Competition Intelligence, Market Dynamics and Challenges, Strategic Growth Initiatives |
The global market was valued at around US$ 16,689.3 million in 2022.
The global market is set to reach a valuation of US$ 25,042.5 million by 2033.
The antimicrobial dressings segment held a 20.2% share in 2022.
Demand in the global market increased at a 2.2% CAGR from 2018 to 2022.
The global market is estimated to reach US$ 17,272.4 million by 2023.
The United States accounted for around 34.9% share of the global market in 2022.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Technological Roadmap
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusion & Exclusion
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Innovation / Development Trends
4. Value Added Insights
4.1. Disease Epidemiology, By Region
4.2. Product USPs / Features Anlaysis
4.3. Reimbursement Scenario
4.4. Regulatory Landscape
4.5. Value Chain Analysis
4.6. PORTER Analysis
4.7. PESTLE Analysis, By Region
5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global GDP Growth Outlook
5.1.2. Global Healthcare Spending Outlook
5.2. Forecast Factors - Relevance & Impact
5.2.1. Growing Prevalence of Diabetic Foot
5.2.2. Increasing Demand for Wound Care Products
5.2.3. Rising Healthcare Expenditure
5.2.4. Rising Geriatric Population Suffering from Pressure Ulcer
5.2.5. Product Launches and Approvals
5.2.6. Historic Growth of Key Companies
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. Global Market Demand (in Volume) Analysis 2016 to 2022 and Forecast, 2023 to 2033
6.1. Historical Market Volume ('000 Units) Analysis, 2016 to 2022
6.2. Current and Future Market Volume ('000 Units) Projections, 2023 to 2033
6.2.1. Y-o-Y Growth Trend Analysis
7. Global Market Pricing Analysis
7.1. Regional Pricing Analysis by Product
7.2. Pricing Break-up
7.2.1. Manufacturer-Level Pricing
7.2.2. Distributor Level Pricing
7.3. Global Average Pricing Analysis Benchmark
7.4. Pricing Assumptions
8. Global Market Demand (in Value or Size in US$ million) Analysis 2016 to 2022 and Forecast, 2023 to 2033
8.1. Revenue Opportunity Scenario
8.2. Historical Market Value (US$ million) Analysis, 2016 to 2022
8.3. Current and Future Market Value (US$ million) Projections, 2023 to 2033
8.3.1. Y-o-Y Growth Trend Analysis
8.3.2. Absolute $ Opportunity Analysis
9. Global Market Analysis 2016 to 2022 and Forecast 2023 to 2033, By Product
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ million) & Volume Analysis by Product, 2016 to 2022
9.3. Current and Future Market Size (US$ million) and Volume Analysis Forecast by Product, 2023 to 2033
9.3.1. Drugs
9.3.1.1. Topical Drugs
9.3.1.1.1. Becaplermin
9.3.1.1.2. Gentamicin
9.3.1.1.3. Minocycline
9.3.1.1.4. Lidocaine
9.3.1.1.5. Sulfadiazine
9.3.1.1.6. Others
9.3.1.2. Oral Drugs
9.3.1.2.1. Colchicine
9.3.1.2.2. Prednisolone
9.3.1.2.3. Aspirin
9.3.1.2.4. Anticoagulants
9.3.1.2.5. Warfarin
9.3.1.2.6. Others
9.3.2. Biologics
9.3.2.1. Biological Skin Substitutes
9.3.2.2. Biomembranes
9.3.3. Negative Pressure Wound Therapy (NPWT) Devices
9.3.3.1. Standalone NPWT Devices
9.3.3.2. Disposable NPWT Devices
9.3.3.3. Portable NPWT Devices
9.3.3.4. NPWT Accessories (Canister)
9.3.4. Advanced Wound Dressings
9.3.4.1. Hydrogels Dressings
9.3.4.2. Semi-Permeable Films Dressings
9.3.4.3. Alginate Dressings
9.3.4.4. Foam Dressings
9.3.4.5. Silicon
9.3.4.5.1. Non-Silicon Dressings
9.3.4.5.2. Hydrocolloid Dressings
9.3.4.6. Collagen Dressing
9.3.4.7. Contact Layer
9.3.4.8. Honey Dressings
9.3.4.9. Super Absorbent Dressings
9.3.4.10. Antimicrobial Dressings
9.3.4.11. Silver Dressings
9.3.4.12. Non-Silver Dressings
9.3.4.13. Other
9.3.4.13.1. Antimicrobial Gels
9.3.4.13.2. Antimicrobial Powder
9.3.4.13.3. Concentrated Surfactant
9.3.4.13.4. Skin Protectants
9.3.4.13.5. Wound Cleansers
9.3.4.13.6. Unna Boots
9.3.4.13.7. Tapes
9.4. Market Attractiveness Analysis by Product
10. Global Market Analysis 2016 to 2022 and Forecast 2023 to 2033, By Wound Type
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ million) Analysis by Wound Type, 2016 to 2022
10.3. Current and Future Market Size (US$ million) Analysis and Forecast by Wound Type, 2023 to 2033
10.3.1. Diabetic Foot Ulcers
10.3.2. Venous Ulcers
10.3.3. Pressure Ulcers
10.3.4. Others Ulcers
10.4. Market Attractiveness Analysis by Wound Type
11. Global Market Analysis 2016 to 2022 and Forecast 2023 to 2033, By Distribution Channel
11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ million) Analysis by Distribution Channel, 2016 to 2022
11.3. Current and Future Market Size (US$ million) Analysis and Forecast by Distribution Channel, 2023 to 2033
11.3.1. Hospitals
11.3.2. Specialty Clinics
11.3.3. Ambulatory Surgical Centers
11.3.4. Long Term Care Centers
11.3.5. Retail Pharmacies & Drug Stores
11.3.6. Hypermarket & Supermarket
11.3.7. Online Sales
11.4. Market Attractiveness Analysis by Age-Group
12. Global Market Analysis 2016 to 2022 and Forecast 2023 to 2033, by Region
12.1. Introduction
12.2. Historical Market Size (US$ million) & Volume Analysis by Region, 2016 to 2022
12.3. Current and Future Market Size (US$ million) and Volume Analysis Forecast by Region, 2023 to 2033
12.3.1. North America
12.3.2. Latin America
12.3.3. East Asia
12.3.4. South Asia & Pacific
12.3.5. Europe
12.3.6. Central Asia
12.3.7. Russia & Belarus
12.3.8. Balkan & Baltic Countries
12.3.9. Middle East & Africa
12.4. Market Attractiveness Analysis by Region
13. North America Market Analysis 2016 to 2022 and Forecast 2023 to 2033
13.1. Introduction
13.2. Historical Market Size (US$ million) & Volume ('000 Units) Trend Analysis by Market Taxonomy, 2016 to 2022
13.3. Market Size (US$ million) & Volume ('000 Units) Forecast by Market Taxonomy, 2023 to 2033
13.3.1. By Country
13.3.1.1. USA
13.3.1.2. Canada
13.3.2. By Product
13.3.3. By Wound Type
13.3.4. By Distribution Channel
13.4. Market Attractiveness Analysis
13.4.1. By Country
13.4.2. By Product
13.4.3. By Wound Type
13.4.4. By Distribution Channel
13.5. Drivers and Restraints - Impact Analysis
14. Latin America Market Analysis 2016 to 2022 and Forecast 2023 to 2033
14.1. Introduction
14.2. Historical Market Size (US$ million) & Volume ('000 Units) Trend Analysis by Market Taxonomy, 2016 to 2022
14.3. Market Size (US$ million) & Volume ('000 Units) Forecast by Market Taxonomy, 2023 to 2033
14.3.1. By Country
14.3.1.1. Brazil
14.3.1.2. Argentina
14.3.1.3. Mexico
14.3.1.4. Rest of Latin America
14.3.2. By Product
14.3.3. By Wound Type
14.3.4. By Distribution Channel
14.4. Market Attractiveness Analysis
14.4.1. By Country
14.4.2. By Product
14.4.3. By Wound Type
14.4.4. By Distribution Channel
15. East Asia Market 2016 to 2022 and Forecast 2023 to 2033
15.1. Introduction
15.2. Historical Market Size (US$ million) & Volume ('000 Units) Trend Analysis by Market Taxonomy, 2016 to 2022
15.3. Market Size (US$ million) & Volume ('000 Units) Forecast by Market Taxonomy, 2023 to 2033
15.3.1. By Country
15.3.1.1. China
15.3.1.2. Japan
15.3.1.3. South Korea
15.3.2. By Product
15.3.3. By Wound Type
15.3.4. By Distribution Channel
15.4. Market Attractiveness Analysis
15.4.1. By Country
15.4.2. By Product
15.4.3. By Wound Type
15.4.4. By Distribution Channel
15.5. Drivers and Restraints - Impact Analysis
16. South Asia & Pacific Market Analysis 2016 to 2022 and Forecast 2023 to 2033
16.1. Introduction
16.2. Historical Market Size (US$ million) & Volume ('000 Units) Trend Analysis by Market Taxonomy, 2016 to 2022
16.3. Market Size (US$ million) & Volume ('000 Units) Forecast by Market Taxonomy, 2023 to 2033
16.3.1. By Country
16.3.1.1. India
16.3.1.2. Indonesia
16.3.1.3. Thailand
16.3.1.4. Philippines
16.3.1.5. Malaysia
16.3.1.6. Vietnam
16.3.1.7. Singapore
16.3.1.8. Australia & New Zealand
16.3.2. By Product
16.3.3. By Wound Type
16.3.4. By Distribution Channel
16.4. Market Attractiveness Analysis
16.4.1. By Country
16.4.2. By Product
16.4.3. By Wound Type
16.4.4. By Distribution Channel
16.5. Drivers and Restraints - Impact Analysis
17. Europe Market 2016 to 2022 and Forecast 2023 to 2033
17.1. Introduction
17.2. Historical Market Size (US$ million) & Volume ('000 Units) Trend Analysis by Market Taxonomy, 2016 to 2022
17.3. Market Size (US$ million) & Volume ('000 Units) Forecast by Market Taxonomy, 2023 to 2033
17.3.1. By Region
17.3.1.1. Western Europe
17.3.1.2. Eastern Europe
17.3.1.3. Germany
17.3.2. By Product
17.3.3. By Wound Type
17.3.4. By Distribution Channel
17.4. Market Attractiveness Analysis
18. Central Asia Market Analysis 2016 to 2022 and Forecast 2023 to 2033
18.1. Introduction
18.2. Historical Market Size (US$ million) & Volume ('000 Units) Trend Analysis by Market Taxonomy, 2016 to 2022
18.3. Market Size (US$ million) & Volume ('000 Units) Forecast by Market Taxonomy, 2023 to 2033
18.4. Market Attractiveness Analysis
18.4.1. By Product
18.4.2. By Wound Type
18.4.3. By Distribution Channel
18.5. Drivers and Restraints - Impact Analysis
19. Russia & Belarus Market Analysis 2016 to 2022 and Forecast 2023 to 2033
19.1. Introduction
19.2. Historical Market Size (US$ million) & Volume ('000 Units) Trend Analysis by Market Taxonomy, 2016 to 2022
19.3. Market Size (US$ million) & Volume ('000 Units) Forecast by Market Taxonomy, 2023 to 2033
19.4. Market Attractiveness Analysis
19.4.1. By Product
19.4.2. By Wound Type
19.4.3. By Distribution Channel
19.5. Drivers and Restraints - Impact Analysis
20. Balkan & Baltic Countries Market Analysis 2016 to 2022 and Forecast 2023 to 2033
20.1. Introduction
20.2. Historical Market Size (US$ million) & Volume ('000 Units) Trend Analysis by Market Taxonomy, 2016 to 2022
20.3. Market Size (US$ million) & Volume ('000 Units) Forecast by Market Taxonomy, 2023 to 2033
20.4. Market Attractiveness Analysis
20.4.1. By Product
20.4.2. By Wound Type
20.4.3. By Distribution Channel
20.5. Drivers and Restraints - Impact Analysis
21. Middle East and Africa (MEA) Market 2016 to 2022 and Forecast 2023 to 2033
21.1. Introduction
21.2. Historical Market Size (US$ million) & Volume ('000 Units) Trend Analysis by Market Taxonomy, 2016 to 2022
21.3. Market Size (US$ million) & Volume ('000 Units) Forecast by Market Taxonomy, 2023 to 2033
21.3.1. By Country
21.3.1.1. GCC Countries
21.3.1.2. Kingdom of Saudi Arabia
21.3.1.3. Turkey
21.3.1.4. Northern Africa
21.3.1.5. South Africa
21.3.1.6. Israel
21.3.2. By Product
21.3.3. By Wound Type
21.3.4. By Distribution Channel
21.4. Market Attractiveness Analysis
21.4.1. By Country
21.4.2. By Product
21.4.3. By Wound Type
21.4.4. By Distribution Channel
22. Market Structure Analysis
22.1. Market Analysis by Tier of Companies
22.2. Market Share Analysis of Top Players
22.3. Key Brands Assessment, By Region
22.4. Pricing Analysis, By Competition
22.5. Market Presence Analysis
22.5.1. By Regional footprint of Players
22.5.2. Product foot print by Players
22.5.3. Channel Foot Print by Players
23. Competition Analysis
23.1. Competition Dashboard
23.2. Key Development Analysis
23.3. Competition Benchmarking
23.4. Competition Deep Dive
23.4.1. Teva Pharmaceuticals
23.4.1.1. Overview
23.4.1.2. Key Financials
23.4.1.3. Product Portfolio
23.4.1.4. Sales Footprint
23.4.1.5. SWOT Analysis
23.4.1.6. Key Development
23.4.1.7. Strategy
23.4.2. Lupin Ltd
23.4.2.1. Overview
23.4.2.2. Key Financials
23.4.2.3. Product Portfolio
23.4.2.4. Sales Footprint
23.4.2.5. SWOT Analysis
23.4.2.6. Key Development
23.4.2.7. Strategy
23.4.3. Cipla Ltd
23.4.3.1. Overview
23.4.3.2. Key Financials
23.4.3.3. Product Portfolio
23.4.3.4. Sales Footprint
23.4.3.5. SWOT Analysis
23.4.3.6. Key Development
23.4.3.7. Strategy
23.4.4. MTF Biologics
23.4.4.1. Overview
23.4.4.2. Key Financials
23.4.4.3. Product Portfolio
23.4.4.4. Sales Footprint
23.4.4.5. SWOT Analysis
23.4.4.6. Key Development
23.4.4.7. Strategy
23.4.5. MIMEDX Group, Inc.
23.4.5.1. Overview
23.4.5.2. Key Financials
23.4.5.3. Product Portfolio
23.4.5.4. Sales Footprint
23.4.5.5. SWOT Analysis
23.4.5.6. Key Development
23.4.5.7. Strategy
23.4.6. Integra Lifesciences
23.4.6.1. Overview
23.4.6.2. Key Financials
23.4.6.3. Product Portfolio
23.4.6.4. Sales Footprint
23.4.6.5. SWOT Analysis
23.4.6.6. Key Development
23.4.6.7. Strategy
23.4.7. Smith and Nephew plc
23.4.7.1. Overview
23.4.7.2. Key Financials
23.4.7.3. Product Portfolio
23.4.7.4. Sales Footprint
23.4.7.5. SWOT Analysis
23.4.7.6. Key Development
23.4.7.7. Strategy
23.4.8. Cardinal Health Inc.
23.4.8.1. Overview
23.4.8.2. Key Financials
23.4.8.3. Product Portfolio
23.4.8.4. Sales Footprint
23.4.8.5. SWOT Analysis
23.4.8.6. Key Development
23.4.8.7. Strategy
23.4.9. 3M
23.4.9.1. Overview
23.4.9.2. Key Financials
23.4.9.3. Product Portfolio
23.4.9.4. Sales Footprint
23.4.9.5. SWOT Analysis
23.4.9.6. Key Development
23.4.9.7. Strategy
23.4.10. Mölnlycke Health Care
23.4.10.1. Overview
23.4.10.2. Key Financials
23.4.10.3. Product Portfolio
23.4.10.4. Sales Footprint
23.4.10.5. SWOT Analysis
23.4.10.6. Key Development
23.4.10.7. Strategy
23.4.11. Medline Industries, Inc.
23.4.11.1. Overview
23.4.11.2. Key Financials
23.4.11.3. Product Portfolio
23.4.11.4. Sales Footprint
23.4.11.5. SWOT Analysis
23.4.11.6. Key Development
23.4.11.7. Strategy
23.4.12. ConvaTec Group plc.
23.4.12.1. Overview
23.4.12.2. Key Financials
23.4.12.3. Product Portfolio
23.4.12.4. Sales Footprint
23.4.12.5. SWOT Analysis
23.4.12.6. Key Development
23.4.12.7. Strategy
23.4.13. Coloplast Corp.
23.4.13.1. Overview
23.4.13.2. Key Financials
23.4.13.3. Product Portfolio
23.4.13.4. Sales Footprint
23.4.13.5. SWOT Analysis
23.4.13.6. Key Development
23.4.13.7. Strategy
23.4.14. B. Braun Holding GmbH & Co. KG
23.4.14.1. Overview
23.4.14.2. Key Financials
23.4.14.3. Product Portfolio
23.4.14.4. Sales Footprint
23.4.14.5. SWOT Analysis
23.4.14.6. Key Development
23.4.14.7. Strategy
23.4.15. Johnson & Johnson Innovation, LLC
23.4.15.1. Overview
23.4.15.2. Key Financials
23.4.15.3. Product Portfolio
23.4.15.4. Sales Footprint
23.4.15.5. SWOT Analysis
23.4.15.6. Key Development
23.4.15.7. Strategy
23.4.16. Stryker Corporation
23.4.16.1. Overview
23.4.16.2. Key Financials
23.4.16.3. Product Portfolio
23.4.16.4. Sales Footprint
23.4.16.5. SWOT Analysis
23.4.16.6. Key Development
23.4.16.7. Strategy
23.4.17. Anika Therapeutics, Inc.
23.4.17.1. Overview
23.4.17.2. Key Financials
23.4.17.3. Product Portfolio
23.4.17.4. Sales Footprint
23.4.17.5. SWOT Analysis
23.4.17.6. Key Development
23.4.17.7. Strategy
23.4.18. Becton, Dickinson and Company
23.4.18.1. Overview
23.4.18.2. Key Financials
23.4.18.3. Product Portfolio
23.4.18.4. Sales Footprint
23.4.18.5. SWOT Analysis
23.4.18.6. Key Development
23.4.18.7. Strategy
23.4.19. Novartis AG
23.4.19.1. Overview
23.4.19.2. Key Financials
23.4.19.3. Product Portfolio
23.4.19.4. Sales Footprint
23.4.19.5. SWOT Analysis
23.4.19.6. Key Development
23.4.19.7. Strategy
23.4.20. Perrigo Company plc
23.4.20.1. Overview
23.4.20.2. Key Financials
23.4.20.3. Product Portfolio
23.4.20.4. Sales Footprint
23.4.20.5. SWOT Analysis
23.4.20.6. Key Development
23.4.20.7. Strategy
23.4.21. AstraZeneca
23.4.21.1. Overview
23.4.21.2. Key Financials
23.4.21.3. Product Portfolio
23.4.21.4. Sales Footprint
23.4.21.5. SWOT Analysis
23.4.21.6. Key Development
23.4.21.7. Strategy
23.4.22. Essity AB (BSN Medical)
23.4.22.1. Overview
23.4.22.2. Key Financials
23.4.22.3. Product Portfolio
23.4.22.4. Sales Footprint
23.4.22.5. SWOT Analysis
23.4.22.6. Key Development
23.4.22.7. Strategy
23.4.23. Boen Healthcare Co., Ltd
23.4.23.1. Overview
23.4.23.2. Key Financials
23.4.23.3. Product Portfolio
23.4.23.4. Sales Footprint
23.4.23.5. SWOT Analysis
23.4.23.6. Key Development
23.4.23.7. Strategy
23.4.24. Hakuzo Medical Asia Co., Ltd
23.4.24.1. Overview
23.4.24.2. Key Financials
23.4.24.3. Product Portfolio
23.4.24.4. Sales Footprint
23.4.24.5. SWOT Analysis
23.4.24.6. Key Development
23.4.24.7. Strategy
23.4.25. Organogenesis Holdings Inc
23.4.25.1. Overview
23.4.25.2. Key Financials
23.4.25.3. Product Portfolio
23.4.25.4. Sales Footprint
23.4.25.5. SWOT Analysis
23.4.25.6. Key Development
23.4.25.7. Strategy
23.4.26. PAUL HARTMANN AG
23.4.26.1. Overview
23.4.26.2. Key Financials
23.4.26.3. Product Portfolio
23.4.26.4. Sales Footprint
23.4.26.5. SWOT Analysis
23.4.26.6. Key Development
23.4.26.7. Strategy
23.4.27. Alleva Medical Ltd. (Devon Medical Products)
23.4.27.1. Overview
23.4.27.2. Key Financials
23.4.27.3. Product Portfolio
23.4.27.4. Sales Footprint
23.4.27.5. SWOT Analysis
23.4.27.6. Key Development
23.4.27.7. Strategy
23.4.28. Olle Larsson Holding AG (Medela AG)
23.4.28.1. Overview
23.4.28.2. Key Financials
23.4.28.3. Product Portfolio
23.4.28.4. Sales Footprint
23.4.28.5. SWOT Analysis
23.4.28.6. Key Development
23.4.28.7. Strategy
23.4.29. Avery Dennison Corporation
23.4.29.1. Overview
23.4.29.2. Key Financials
23.4.29.3. Product Portfolio
23.4.29.4. Sales Footprint
23.4.29.5. SWOT Analysis
23.4.29.6. Key Development
23.4.29.7. Strategy
23.4.30. Oneness Biotech
23.4.30.1. Overview
23.4.30.2. Key Financials
23.4.30.3. Product Portfolio
23.4.30.4. Sales Footprint
23.4.30.5. SWOT Analysis
23.4.30.6. Key Development
23.4.30.7. Strategy
23.4.31. Vericel Corporation
23.4.31.1. Overview
23.4.31.2. Key Financials
23.4.31.3. Product Portfolio
23.4.31.4. Sales Footprint
23.4.31.5. SWOT Analysis
23.4.31.6. Key Development
23.4.31.7. Strategy
23.4.32. Marine Polymer Technologies Inc
23.4.32.1. Overview
23.4.32.2. Key Financials
23.4.32.3. Product Portfolio
23.4.32.4. Sales Footprint
23.4.32.5. SWOT Analysis
23.4.32.6. Key Development
23.4.32.7. Strategy
23.4.33. SIGVARIS GROUP
23.4.33.1. Overview
23.4.33.2. Key Financials
23.4.33.3. Product Portfolio
23.4.33.4. Sales Footprint
23.4.33.5. SWOT Analysis
23.4.33.6. Key Development
23.4.33.7. Strategy
23.4.34. Taro Pharmaceuticals
23.4.34.1. Overview
23.4.34.2. Key Financials
23.4.34.3. Product Portfolio
23.4.34.4. Sales Footprint
23.4.34.5. SWOT Analysis
23.4.34.6. Key Development
23.4.34.7. Strategy
23.4.35. Prasco Laboratories.
23.4.35.1. Overview
23.4.35.2. Key Financials
23.4.35.3. Product Portfolio
23.4.35.4. Sales Footprint
23.4.35.5. SWOT Analysis
23.4.35.6. Key Development
23.4.35.7. Strategy
24. Assumptions and Acronyms Used
25. Research Methodology
Healthcare
January 2023
REP-GB-16473
291 pages
Explore Healthcare Insights
View Reports
Chronic Wound Care Market
